{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=44", "query": { "intervention": "Combination 400", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 1062, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+400&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T19:49:46.881Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03386838", "title": "An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "BMS-986205", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-03-28", "completion_date": "2018-04-19", "has_results": false, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386838" }, { "nct_id": "NCT04736706", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Belzutifan", "type": "DRUG" }, { "name": "Pembrolizumab/Quavonlimab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1688, "start_date": "2021-04-14", "completion_date": "2027-04-22", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 33, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04736706" }, { "nct_id": "NCT01221298", "title": "A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HCV", "Chronic Hepatitis C Infection", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-072", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2010-10", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 4, "location_summary": "Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221298" }, { "nct_id": "NCT01896921", "title": "Switch to Maraviroc + Integrase Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Switch to Maraviroc + Raltegravir or Dolutegravir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2013-09", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01896921" }, { "nct_id": "NCT00114959", "title": "Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloid Leukemia, Chronic", "Myeloid Leukemia, Chronic, Accelerated-Phase", "Blast Phase", "Myeloid Leukemia, Chronic, Chronic-Phase" ], "interventions": [ { "name": "Homoharringtonine", "type": "DRUG" }, { "name": "Imatinib Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ChemGenex Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 15, "start_date": "2005-10", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2015-01-15", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00114959" }, { "nct_id": "NCT02560779", "title": "Trial of TRC105 and Sorafenib in Patients With HCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Carotuximab (TRC105)", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tracon Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-11", "completion_date": "2019-08", "has_results": true, "last_update_posted_date": "2020-07-17", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Cleveland, Ohio • Houston, Texas", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02560779" }, { "nct_id": "NCT05430009", "title": "Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Metastases", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Liver SBRT", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "VA Ann Arbor Healthcare System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-06-17", "completion_date": "2026-06-15", "has_results": false, "last_update_posted_date": "2022-08-01", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05430009" }, { "nct_id": "NCT01015664", "title": "Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01015664" }, { "nct_id": "NCT00023244", "title": "Steroid Withdrawal in Pediatric Kidney Transplant Recipients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End-Stage Renal Disease" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Bactrim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "20 Years", "sex": "ALL", "summary": "1 Day to 20 Years" }, "enrollment_count": 274, "start_date": "2001-01", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Diego, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023244" }, { "nct_id": "NCT01515787", "title": "PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "FOLFOX (chemotherapy)", "type": "DRUG" }, { "name": "5 FUCMT (chemoradiation)", "type": "OTHER" }, { "name": "surgery", "type": "PROCEDURE" }, { "name": "magnetic resonance imaging or endorectal ultrasound", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1194, "start_date": "2012-06-12", "completion_date": "2024-06-30", "has_results": true, "last_update_posted_date": "2024-02-02", "last_synced_at": "2026-11-11T19:49:46.881Z", "location_count": 1048, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 613 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01515787" } ] }